Rentschler Biopharma, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization (CRDO) and a leader in formulation research and development for biopharmaceuticals, have announced a strategic collaboration.

Together, the companies will offer clients services from early formulation through to commercial manufacturing, combining their complementary expertise to help accelerate a product’s path to market. Clients will have access to a unified interface and aligned project teams, reducing tech transfer risks and enabling faster progression from early development to clinical and commercial stages.

Coriolis Pharma brings a combination of in silico and wet lab formulation and drug product development expertise, scientific depth, and advanced analytical capabilities to this collaboration. Coriolis supports every drug development phase from R&D to GMP.

Rentschler Biopharma brings extensive experience in bioprocess development and manufacturing for multiple biotherapeutics, backed by a strong track record of reliability and quality. With a commitment to client-centric solutions, the company provides robust support from process development through to commercial supply. By focusing on technical excellence, long-term partnerships, and tailored solutions, Rentschler Biopharma ensures successful outcomes at every stage of the project.

Benedikt von Braunmühl, CEO of Rentschler Biopharma, said: “This marks an important step for both our organizations and for our global clients, and their patients. Coriolis Pharma shares our focus on technical excellence, reliability, as well as our client-centric approach. By bringing together our individual areas of excellence, bioprocess development and manufacturing on our side, and scientific and analytical expertise in formulation development at Coriolis, we look forward to addressing complex challenges across the biopharmaceutical value chain more efficiently and faster.”

Silvia Steyrer-Gruber, CEO of Coriolis Pharma, added: “This collaboration is a testament to our Coriolis partnering strategy, which fosters synergistic relationships across the biopharma ecosystem. Together, we can provide clients with connected, science-driven solutions that help them move their projects forward towards success. Our teams look forward to working closely with Rentschler Biopharma on this collaboration.”

The integrated service offering will be available to clients starting December 2025.